|
- label - accessdata. fda. gov
These highlights do not include all the information needed to use TRYNGOLZA safely and effectively See full prescribing information for TRYNGOLZA
- Tryngolza: Package Insert Prescribing Information MOA
Tryngolza package insert prescribing information for healthcare professionals Includes: indications, dosage, adverse reactions and pharmacology
- Support Resources | TRYNGOLZA® (olezarsen) Injection
Access downloadable resources and watch videos to support your TRYNGOLZA® treatment journey See Safety Full Prescribing Information
- Tislelizumab
WHAT IS TISLELIZUMAB? Tislelizumab is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high afinity and binding specificity against PD-1 Tislelizumab is the first medicine to emerge from BeOne’s immuno-oncology biologics program, and the foundational asset of BeOne’s solid tumor portfolio
- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not . . .
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRYNGOLZA safely and effectively See full prescribing information for TRYNGOLZA
- FDA Label for Tryngolza Injection, Solution Subcutaneous . . .
Table of Contents Tryngolza Product Label The following document was submitted to the FDA by the labeler of this product Ionis Pharmaceuticals, Inc The document includes published materials associated whith this product with the essential scientific information about this product as well as other prescribing information
- Tryngolza | European Medicines Agency (EMA)
Tryngolza can only be obtained with a prescription and is available as a solution for injection in prefilled pens It is injected once a month under the skin in the abdomen (belly), the front of the thigh or the back of the upper arm Patients or their carers can inject Tryngolza themselves once they have been trained For more information about using Tryngolza, see the package leaflet or
- Tevimbra US PI - BeiGene
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TEVIMBRA safely and effectively See full prescribing information for TEVIMBRA TEVIMBRA® (tislelizumab-jsgr) injection, for intravenous use Initial U S Approval: 2024
|
|
|